KA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners...

Stats
Today's Volume	818 576
Average Volume	354 961
Market Cap	6.96M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.210 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.500
ATR14	$0.0130 (2.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Iadonato Shawn	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Philips Craig W.	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Baker Keith	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Guillaudeux Thierry	Buy	225 000	Stock Option (Right to Buy)
2023-12-06	Bartoszek Raymond J.	Buy	250	Common Stock

INSIDER POWER
92.47
Last 63 transactions
Buy: 2 025 106 \| Sell: 94 301

Volume Correlation

Long: -0.26 (neutral)

Short: 0.37 (neutral)

Signal:(56.334) Neutral

Kineta, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kineta, Inc. Correlation - Currency/Commodity

0.30
( neutral )

0.23
( neutral )

0.00
( neutral )

0.13
( neutral )

Kineta, Inc. Financials

Annual	2023
Revenue:	$5.44M
Gross Profit:	$5.43M (99.83 %)
EPS:	$-1.280

Q4	2023
Revenue:	$0
Gross Profit:	$-4 000.00 (0.00 %)
EPS:	$-0.260

Q3	2023
Revenue:	$0
Gross Profit:	$-189 000 (0.00 %)
EPS:	$-0.460

Q2	2023
Revenue:	$5.16M
Gross Profit:	$4.98M (96.43 %)
EPS:	$0.0388

Financial Reports:

No articles found.

Kineta, Inc.

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.